Results 31 to 40 of about 11,372 (280)
EUCAST technical note on anidulafungin [PDF]
Clinical Microbiology and Infection, 2011 The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing has determined breakpoints for anidulafungin for Candida spp. This Technical Note is based on the EUCAST anidulafungin rationale document (available at: http://www.eucast.org). Species-specific breakpoints for C.
Arendrup, M.C. +5 more
openaire +4 more sources
A New Antifungal-Loaded Sol-Gel Can Prevent Candida albicans Prosthetic Joint Infection
Antibiotics, 2021 Fungal PJI is one of the most feared complications after arthroplasty. Although a rare finding, its high associated morbidity and mortality makes it an important object of study. The most frequent species causing fungal PJI is C. albicans. New technology
Hugo Garlito-Díaz +9 more
doaj +1 more source
In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model. [PDF]
J Fungi (Basel)Balázsi D +10 more
europepmc +2 more sources
Antimicrobial Agents and Chemotherapy, 2021 A total of 15 Candida auris isolates from the SENTRY antimicrobial surveillance program between 2006 and 2019 were combined with 21 isolates from other collections for the evaluation of antifungal susceptibility and synergy against anidulafungin plus ...
M. Pfaller +5 more
semanticscholar +1 more source
Anidulafungin for the treatment of invasive candidiasis [PDF]
Clinical Microbiology and Infection, 2011 Candidaemia/invasive candidiasis (C/IC) is the most frequently occurring invasive fungal infection worldwide, with a particularly strong impact and high incidence in the intensive-care unit, where there is a need for new treatment options and strategies. The echinocandin anidulafungin has broad in vitro activity against a wide range of Candida species,
Cornelia Lass-Flörl +2 more
openaire +3 more sources
Journal of Fungi, 2022 The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine of a patient following prolonged exposure to echinocandins (38 days of micafungin followed ...
Maria Siopi +12 more
doaj +1 more source
Journal of Biomolecular Structure and Dynamics, 2021 COVID-19, for which no confirmed therapeutic agents are available, has claimed over 48,14,000 lives globally. A feasible and quicker method to resolve this problem may be ‘drug repositioning’. We investigated selected FDA and WHO-EML approved drugs based
S. Dey +7 more
semanticscholar +1 more source
Clinical drug investigation, 2021 Solid tumors are a common predisposing factor for invasive candidiasis (IC) or candidemia due to IC. Post hoc analysis of patient-level efficacy and safety data from six studies of anidulafungin (with similar protocols/endpoints) in adults with IC ...
F. D. De Rosa +4 more
semanticscholar +1 more source
In vitro anidulafungin activity against yeasts – system and disseminated mycosis pathogens
Онкогематология, 2015 We analyzed susceptibility to anidulafungin of yeasts clinical strains of Candida (14 species), Cryptococcus (1 species), Geotrichum (1 species), Rhodotorula (1 species) and Saccharomyces (1 species).
A. B. Kulko
doaj +1 more source
Set of Classical PCRs for Detection of Mutations in Candida glabrata FKS Genes Linked with Echinocandin Resistance [PDF]
, 2014 Clinical echinocandin resistance among Candida glabrata strains is increasing, especially in the United States. Antifungal susceptibility testing is considered mandatory to guide therapeutic decisions.
Afeltra, Javier +7 more
core +2 more sources